Puma Biotechnology Stock Surges Past 200-Day Average

Shares of the cancer drug maker reach a new high, but what's next for the stock?

Apr. 8, 2026 at 8:13am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white macro photograph of gears, levers, and other industrial machinery, conveying the tangible, physical nature of the financial markets.An extreme close-up of the complex inner workings of the financial industry reflects the volatility and momentum driving biotech stocks like Puma Biotechnology.Los Angeles Today

Shares of Puma Biotechnology (NASDAQ:PBYI) rose above their 200-day moving average on Tuesday, trading as high as $7.02 per share. The biopharmaceutical company, which focuses on developing targeted cancer therapies, saw its stock close the day at $6.97 with trading volume of over 300,000 shares.

Why it matters

Puma Biotechnology's stock price crossing above the 200-day moving average is seen as a bullish technical indicator, suggesting the stock may have momentum to continue its recent gains. However, analysts remain divided on the company's outlook, with one rating the stock a 'hold' while another recently upgraded it to a 'strong buy'.

The details

Puma Biotechnology's lead product is the breast cancer drug Nerlynx, which received FDA approval in 2017 for extended adjuvant treatment of early-stage HER2-positive breast cancer. The company reported earnings of $0.26 per share in its most recent quarter, beating analyst estimates. Puma has a market capitalization of $354.61 million and a price-to-earnings ratio of 11.43.

  • Puma Biotechnology's stock crossed above its 200-day moving average of $5.86 on Tuesday, April 8, 2026.
  • In its most recent earnings report on February 26, 2026, Puma Biotechnology reported quarterly earnings of $0.26 per share.

The players

Puma Biotechnology, Inc.

A late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for oncology patients. The company's lead product is the breast cancer drug Nerlynx.

Weiss Ratings

A research firm that currently rates Puma Biotechnology's stock as a 'hold (c+)'.

Wall Street Zen

A research firm that recently upgraded Puma Biotechnology's stock from a 'buy' rating to a 'strong-buy' rating.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching to see if Puma Biotechnology's stock can maintain its momentum and continue trading above the 200-day moving average. The company's next earnings report, expected in the coming months, will also be a key catalyst for the stock.

The takeaway

Puma Biotechnology's stock price crossing above its 200-day moving average is a positive technical signal, but the company's long-term outlook remains mixed according to Wall Street analysts. Investors will need to weigh the potential upside of the company's cancer drug pipeline against ongoing challenges facing the business.